Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
APRE 
Aprea Therapeutics Inc (APRE)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/17/2025: APRE (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
3 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $10.5
1 Year Target Price $10.5
| 1 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -40.93% | Avg. Invested days 39 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/17/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 8.48M USD | Price to earnings Ratio - | 1Y Target Price 10.5 |
Price to earnings Ratio - | 1Y Target Price 10.5 | ||
Volume (30-day avg) 3 | Beta 1.58 | 52 Weeks Range 1.41 - 5.01 | Updated Date 09/17/2025 |
52 Weeks Range 1.41 - 5.01 | Updated Date 09/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.3 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -2868.3% |
Management Effectiveness
Return on Assets (TTM) -39.12% | Return on Equity (TTM) -67.54% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -8056445 | Price to Sales(TTM) 10.08 |
Enterprise Value -8056445 | Price to Sales(TTM) 10.08 | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 0.35 | Shares Outstanding 5825260 | Shares Floating 4635801 |
Shares Outstanding 5825260 | Shares Floating 4635801 | ||
Percent Insiders 11.3 | Percent Institutions 31.2 |
Upturn AI SWOT
Aprea Therapeutics Inc
Company Overview
History and Background
Aprea Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics. It was founded in 2003 and went public in 2019. Initially focused on small molecule therapies, it pivoted to oligonucleotide therapeutics.
Core Business Areas
- Oncology Drug Development: Focuses on developing new therapies for cancer treatment. Their leading product is oligonucleotide therapies designed to target specific cancer-causing genes.
Leadership and Structure
The company is led by a Board of Directors and an executive management team with experience in biotechnology and pharmaceuticals.
Top Products and Market Share
Key Offerings
- ATR-008: Aprea's lead product candidate, an oligonucleotide therapeutic targeting ATR. It is in clinical development for different types of cancer. Market share data is not publicly available as it is still in clinical development. Competitors developing ATR inhibitors include Merck KGaA, Vertex Pharmaceuticals, and Bayer.
Market Dynamics
Industry Overview
The oncology drug development market is highly competitive and rapidly evolving, with significant investment in novel therapies.
Positioning
Aprea Therapeutics is positioned as a biotechnology company focused on innovative therapies. Its competitive advantage lies in its oligonucleotide technology.
Total Addressable Market (TAM)
The global cancer therapeutics market is estimated to be worth hundreds of billions of dollars. Aprea targets specific genetic mutations within that large TAM.
Upturn SWOT Analysis
Strengths
- Novel oligonucleotide technology
- Strong intellectual property position
- Experienced management team
- Clinical stage assets
Weaknesses
- Limited financial resources compared to larger pharmaceutical companies
- Reliance on clinical trial outcomes
- Single lead product candidate
- High cash burn rate
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion of pipeline to include other oligonucleotide therapies
- Positive clinical trial results
- FDA approval of ATR-008
Threats
- Clinical trial failures
- Competition from other cancer therapies
- Regulatory hurdles
- Patent challenges
- Economic downturns
Competitors and Market Share
Key Competitors
- MRK
- VRTX
- BAYRY
Competitive Landscape
Aprea faces strong competition from established pharmaceutical companies with greater resources. Its success depends on demonstrating the clinical efficacy of its therapies.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is dependent on clinical trial progress and financing activities.
Future Projections: Future growth is contingent upon successful clinical trial outcomes and regulatory approvals.
Recent Initiatives: Aprea is focused on advancing ATR-008 through clinical trials.
Summary
Aprea Therapeutics is a high-risk, high-reward biotechnology company focused on developing innovative cancer therapies. Success hinges on positive clinical trial results and regulatory approval for their lead product candidate. The company's financial health and ability to secure partnerships will be crucial for long-term growth. Investors should be aware of the inherent risks involved in investing in clinical-stage biotechnology companies.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Company Website
- Market Research Reports
- Financial News Outlets
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. The information provided is based on publicly available data and may not be complete or accurate. Investing in biotechnology companies involves significant risks, and investors should conduct their own due diligence before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Aprea Therapeutics Inc
Exchange NASDAQ | Headquaters Doylestown, PA, United States | ||
IPO Launch date 2019-10-03 | Co-Founder, CEO, President & Director Dr. Oren Gilad Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 8 | Website https://aprea.com |
Full time employees 8 | Website https://aprea.com | ||
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidates are APR-1051, an orally bioavailable small-molecule inhibitor of WEE1 kinase that is in Phase 1 clinical trial for the treatment of patients with advanced solid tumors with biomarkers; and ATRN-119, an ATR inhibitor, which is in Phase 1/2a clinical trial for solid tumor indications. The company is headquartered in Doylestown, Pennsylvania.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.